secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065672
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025
--------------------------------------------------------------------------------

- Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)
- Net income $19.0M ($0.11/sh) vs $16.6M ($0.10/sh) in Q1 2024; cash $681.6M
- DAYBUE record 954 unique patients shipped; 30% field force expansion completed; first EU patient served
- COMPASS PWS Phase 3 topline results now expected early Q4 2025 (accelerated); if positive, NDA submission Q1 2026
- 2025 guidance reiterated: total rev $1.03-1.095B; R&D expense raised to $330-350M due to study acceleration

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/0000950170-25-065672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/acad-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer